DNA
Price
$15.96
Change
+$1.14 (+7.69%)
Updated
Oct 8, 04:18 PM (EDT)
Capitalization
877.34M
VCYT
Price
$35.27
Change
+$0.66 (+1.91%)
Updated
Oct 8, 12:52 PM (EDT)
Capitalization
2.72B
34 days until earnings call
Interact to see
Advertisement

DNA vs VCYT

Header iconDNA vs VCYT Comparison
Open Charts DNA vs VCYTBanner chart's image
Ginkgo Bioworks Holdings
Price$15.96
Change+$1.14 (+7.69%)
Volume$855
Capitalization877.34M
Veracyte
Price$35.27
Change+$0.66 (+1.91%)
Volume$1.7K
Capitalization2.72B
DNA vs VCYT Comparison Chart in %
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. VCYT commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a StrongBuy and VCYT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (DNA: $14.82 vs. VCYT: $34.61)
Brand notoriety: DNA and VCYT are both not notable
DNA represents the Biotechnology, while VCYT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: DNA: 87% vs. VCYT: 67%
Market capitalization -- DNA: $877.34M vs. VCYT: $2.72B
DNA [@Biotechnology] is valued at $877.34M. VCYT’s [@Medical Specialties] market capitalization is $2.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B. The average market capitalization across the [@Medical Specialties] industry is $11.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, DNA is a better buy in the long-term than VCYT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 3 bullish TA indicator(s).

  • DNA’s TA Score: 5 bullish, 5 bearish.
  • VCYT’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, DNA is a better buy in the short-term than VCYT.

Price Growth

DNA (@Biotechnology) experienced а +1.65% price change this week, while VCYT (@Medical Specialties) price change was +0.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.87%. For the same industry, the average monthly price growth was +18.79%, and the average quarterly price growth was +86.80%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.13%. For the same industry, the average monthly price growth was +7.39%, and the average quarterly price growth was +39.48%.

Reported Earning Dates

VCYT is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+8.87% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+1.13% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCYT($2.72B) has a higher market cap than DNA($877M). DNA YTD gains are higher at: 50.916 vs. VCYT (-12.601). VCYT has higher annual earnings (EBITDA): 52M vs. DNA (-292.97M). DNA has more cash in the bank: 474M vs. VCYT (321M). VCYT has less debt than DNA: VCYT (50.6M) vs DNA (429M). VCYT has higher revenues than DNA: VCYT (479M) vs DNA (231M).
DNAVCYTDNA / VCYT
Capitalization877M2.72B32%
EBITDA-292.97M52M-563%
Gain YTD50.916-12.601-404%
P/E RatioN/A101.79-
Revenue231M479M48%
Total Cash474M321M148%
Total Debt429M50.6M848%
FUNDAMENTALS RATINGS
VCYT: Fundamental Ratings
VCYT
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
92
SMR RATING
1..100
89
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
57
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNAVCYT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 29 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIIRX29.75N/A
N/A
Nuveen Core Equity A
STSAX7.13N/A
N/A
Allspring Common Stock C
CHUSX31.25N/A
N/A
Alger Global Equity A
FJACX11.75N/A
N/A
Fidelity Series Small Cap Discovery
BLUIX16.44N/A
N/A
Blueprint Adaptive Growth Allc Instl

VCYT and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCYT
1D Price
Change %
VCYT100%
-3.97%
NTLA - VCYT
69%
Closely correlated
-0.49%
VCEL - VCYT
60%
Loosely correlated
-1.87%
AXON - VCYT
58%
Loosely correlated
-0.97%
DNA - VCYT
57%
Loosely correlated
-0.34%
GH - VCYT
55%
Loosely correlated
+0.09%
More